News

Lilly buys Calytrix Bio for up to $1.5B in blood cancer push

What's the deal? Eli Lilly has agreed to acquire Calytrix BioDealroom has a profile for this one. Try Dealroom →, a Wellesley Hills, Massachusetts startup developing precision therapies for rare blood cancers, for up to $1.5 billion in cash. The payout includes an upfront sum and later payments tied to clinical and regulatory milestones. Calytrix did not disclose the guaranteed cash or when the deal closes.

What each side brings: Calytrix is working on treatments for myelofibrosis and essential thrombocythemia, forms of myeloproliferative neoplasms that cause the bone marrow to overproduce abnormal blood cells. Its lead asset is a preclinical "biparatopic" antibody targeting mutant calreticulin (mCALR), designed to attack disease-driving cells while sparing healthy ones. The drug has not yet entered human trials.

Why now? Current therapies, such as JAK inhibitors like Incyte's Jakafi, mainly manage symptoms rather than target the underlying mutations. "Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms," said Brad Prosek, Calytrix's president and chief executive officer.

What's the endgame? The deal strengthens Lilly's footprint in hematology, where it already sells the approved blood cancer medicine Jaypirca. It follows Lilly's $2.3 billion purchase of Ajax Therapeutics earlier this year, another bet on the field.

Calytrix was founded in 2025 by J.P. Morgan Life Sciences Private Capital, backed by Westlake BioPartners and Avoro VenturesDealroom has a profile for this one. Try Dealroom →.

The signal: This is Lilly's 15th announced company acquisition in 2026, bringing its yearly spend past $30 billion and making it the sector's most prolific dealmaker. The buyout also reflects rising interest in myeloproliferative neoplasms, with rivals like Galecto also chasing mCALR-driven disease. For now, the payoff depends on a program that has yet to reach the clinic.

Read more: biopharmadive.com, prnewswire.com, Reuters

Image credit: Calytrix Bio, via PR Newswire

More top stories